The connectivity map links iron regulatory protein-1-mediated inhibition of hypoxia-inducible factor-2a translation to the anti-inflammatory 15-deoxy-delta12,14-prostaglandin J2.

Hypoxia-inducible factors 1 and 2 (HIF1 and HIF2) are heterodimeric transcription factors consisting of alpha regulatory subunits and a constitutively expressed beta subunit. The expression of alpha regulatory subunits is promoted by hypoxia, cancer-associated mutations, and inflammatory cytokines. Thus, HIF1 and HIF2 provide a molecular link between cancer and inflammation. We have recently identified novel small molecules that selectively inhibit translation of the HIF2a message and thereby powerfully inhibit the expression of HIF2a target genes. We report here that Connectivity Map analysis links three of these compounds to the anti-inflammatory cytokine 15-deoxy-Delta(12,14)-prostaglandin J(2) (PGJ(2)). As with our identified compounds, PGJ(2) inhibits translation of the HIF2a message in a mammalian target of rapamycin-independent manner by promoting the binding of iron regulatory protein-1 (IRP1) to a noncanonical iron responsive element (IRE) embedded within the 5'-untranslated region of the HIF2a message. The IRE is necessary and sufficient for mediating the effect. Mutation of the IRE sequence, or downregulation of IRP1 expression, blocks the effect of PGJ(2) on HIF2a translation. This is the first report of an endogenous natural molecule regulating HIF2a translation, and it suggests that part of the anti-inflammatory and putative antineoplastic effects of PGJ(2) may be mediated through inhibition of HIF2a within tumor epithelial cells themselves and/or mesenchymal cells of the tumor microenvironment.

[1]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[2]  P. Dallman,et al.  Iron deficiency and neutrophil function: different rates of correction of the depressions in oxidative burst and myeloperoxidase activity after iron treatment. , 1987, Blood.

[3]  Elizabeth C. Theil,et al.  Loops and Bulge/Loops in Iron-responsive Element Isoforms Influence Iron Regulatory Protein Binding , 1998, The Journal of Biological Chemistry.

[4]  S. Narumiya,et al.  Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice , 2001, Nature Medicine.

[5]  A. Levine,et al.  Prostaglandin E2 Induces Hypoxia-inducible Factor-1α Stabilization and Nuclear Localization in a Human Prostate Cancer Cell Line* , 2002, The Journal of Biological Chemistry.

[6]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[7]  A. Tarnawski,et al.  Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy , 2002, Nature Medicine.

[8]  Christine C. Hudson,et al.  Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin , 2002, Molecular and Cellular Biology.

[9]  K. Pantopoulos,et al.  The prolyl 4‐hydroxylase inhibitor ethyl‐3,4‐dihydroxybenzoate generates effective iron deficiency in cultured cells , 2002, FEBS letters.

[10]  G. Semenza,et al.  Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. , 2003, Cancer research.

[11]  R. Jaenisch,et al.  HIF-1α Is Essential for Myeloid Cell-Mediated Inflammation , 2003, Cell.

[12]  T. Lawrence,et al.  Inducible cyclooxygenase‐derived 15deoxy Δ 12‐14PGJ2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  M. Reilly,et al.  Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. , 2003, The Journal of clinical investigation.

[14]  A. Giaccia,et al.  HIF-1 as a target for drug development , 2003, Nature Reviews Drug Discovery.

[15]  W. Kaelin,et al.  Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth , 2003, PLoS biology.

[16]  T. Golub,et al.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.

[17]  E. Hafen,et al.  Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. , 2004, Genes & development.

[18]  Nahum Sonenberg,et al.  A Novel Function of the MA-3 Domains in Transformation and Translation Suppressor Pdcd4 Is Essential for Its Binding to Eukaryotic Translation Initiation Factor 4A , 2004, Molecular and Cellular Biology.

[19]  O. Iliopoulos,et al.  Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. , 2004, Molecular cancer research : MCR.

[20]  K. Pantopoulos.  Iron Metabolism and the IRE/IRP Regulatory System: An Update , 2004, Annals of the New York Academy of Sciences.

[21]  S. Dey,et al.  Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ , 2004 .

[22]  E. Schmidt,et al.  hnRNP K Binds a Core Polypyrimidine Element in the Eukaryotic Translation Initiation Factor 4E (eIF4E) Promoter, and Its Regulation of eIF4E Contributes to Neoplastic Transformation , 2005, Molecular and Cellular Biology.

[23]  S. Dey,et al.  Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. , 2005, Cancer research.

[24]  O. Iliopoulos.  Molecular biology of renal cell cancer and the identification of therapeutic targets. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[26]  T. Rouault.  The role of iron regulatory proteins in mammalian iron homeostasis and disease , 2006, Nature chemical biology.

[27]  Y. Surh,et al.  15 -Deoxy -Δ12,14 -prostaglandin J2 as a potential endogenous regulator of redox-sensitive transcription factors , 2006 .

[28]  E. Cohen-Jonathan-Moyal,et al.  Activation of RhoB by hypoxia controls hypoxia-inducible factor-1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells. , 2006, Cancer research.

[29]  Henry J. Lin,et al.  Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in ApcMin/+ mice. , 2007, Cancer research.

[30]  Mayka Sanchez,et al.  Iron-regulatory proteins limit hypoxia-inducible factor-2α expression in iron deficiency , 2007, Nature Structural &Molecular Biology.

[31]  Jian Zhou,et al.  Inhibition of VEGF Expression by Targeting HIF-1α with Small Interference RNA in Human RPE Cells , 2007, Ophthalmologica.

[32]  S. Jang,et al.  Anti‐inflammatory lipid mediator 15d‐PGJ2 inhibits translation through inactivation of eIF4A , 2007, The EMBO journal.

[33]  Geoff Bellingan,et al.  Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyΔ12–14 PGJ2 , 2007, Proceedings of the National Academy of Sciences.

[34]  T. Golub,et al.  Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. , 2008, Molecular cell.

[35]  R. Fleming.  Iron and inflammation: cross-talk between pathways regulating hepcidin , 2008, Journal of Molecular Medicine.

[36]  M. Ohh,et al.  Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2* , 2008, Journal of Biological Chemistry.

[37]  Katerina Akassoglou,et al.  NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α , 2008, Nature.

[38]  M. Arenas,et al.  15-Deoxy-Δ12,14-prostaglandin-J2 reveals a new pVHL-independent, lysosomal-dependent mechanism of HIF-1α degradation , 2009, Cellular and Molecular Life Sciences.